Genovate Biotechnology Co Ltd (4130) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Genovate Biotechnology Co Ltd (4130) has a cash flow conversion efficiency ratio of 0.012x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$16.93 Million ≈ $533.39K USD) by net assets (NT$1.38 Billion ≈ $43.49 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see 4130 market cap for the company's overall valuation and market capitalisation.
Genovate Biotechnology Co Ltd - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how Genovate Biotechnology Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Genovate Biotechnology Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Genovate Biotechnology Co Ltd ranked by their cash flow conversion efficiency. Explore Genovate Biotechnology Co Ltd (4130) cash earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
OBI Pharma
TWO:4174
|
-0.132x |
|
MFS High Income Municipal Closed Fund
NYSE:CXE
|
0.024x |
|
Equillium Inc
NASDAQ:EQ
|
-0.273x |
|
Topower Co Ltd
TWO:3226
|
0.035x |
|
Hansae Yes24
KO:016450
|
0.105x |
|
Hwaseung Enterprise Co Ltd
KO:241590
|
0.018x |
|
Jw Life Science Corp
KO:234080
|
0.065x |
|
Cheil Electric Wiring Devices Co. Ltd.
KQ:199820
|
0.054x |
Annual Cash Flow Conversion Efficiency for Genovate Biotechnology Co Ltd (2015–2025)
The table below shows the annual cash flow conversion efficiency of Genovate Biotechnology Co Ltd from 2015 to 2025. View Genovate Biotechnology Co Ltd (4130) share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | NT$1.38 Billion ≈ $43.49 Million |
NT$43.79 Million ≈ $1.38 Million |
0.032x | -16.58% |
| 2024-12-31 | NT$1.45 Billion ≈ $45.66 Million |
NT$55.11 Million ≈ $1.74 Million |
0.038x | -34.11% |
| 2023-12-31 | NT$1.47 Billion ≈ $46.27 Million |
NT$84.78 Million ≈ $2.67 Million |
0.058x | +5293.20% |
| 2022-12-31 | NT$1.41 Billion ≈ $44.45 Million |
NT$1.51 Million ≈ $47.57K |
0.001x | +108.55% |
| 2021-12-31 | NT$1.38 Billion ≈ $43.44 Million |
NT$-17.26 Million ≈ $-543.75K |
-0.013x | -120.50% |
| 2020-12-31 | NT$1.43 Billion ≈ $44.93 Million |
NT$87.08 Million ≈ $2.74 Million |
0.061x | +93.55% |
| 2019-12-31 | NT$1.41 Billion ≈ $44.37 Million |
NT$44.43 Million ≈ $1.40 Million |
0.032x | -21.55% |
| 2018-12-31 | NT$1.56 Billion ≈ $49.26 Million |
NT$62.88 Million ≈ $1.98 Million |
0.040x | +105.73% |
| 2017-12-31 | NT$1.60 Billion ≈ $50.40 Million |
NT$31.27 Million ≈ $985.27K |
0.020x | -37.70% |
| 2016-12-31 | NT$2.25 Billion ≈ $70.86 Million |
NT$70.58 Million ≈ $2.22 Million |
0.031x | +104.92% |
| 2015-12-31 | NT$2.12 Billion ≈ $66.93 Million |
NT$32.53 Million ≈ $1.02 Million |
0.015x | -- |
About Genovate Biotechnology Co Ltd
Genovate Biotechnology Co., Ltd. engages in the research, development, manufacture, production, and sale of products to prevent and treat diseases caused by viruses and bacteria in Taiwan. It provides drugs, APIs, intermediates, and release agents for the treatment of cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune diseases; and controlled-release dosage forms of Western medi… Read more